Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Relapsing-remitting multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Relapsing-remitting multiple sclerosis: Overview
Relapsing-remitting multiple sclerosis (RRMS) - the most common disease course – is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission.RRMS can be further characterized as either active (with relapses and/or evidence of new MRI activity over a specified period of time) or not active, as well as worsening (a confirmed increase in disability following a relapse) or not worsening. Approximately 85 percent of people with MS are initially diagnosed with RRMS.
'Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing-remitting multiple sclerosis pipeline landscape is provided which includes the disease overview and Relapsing-remitting multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing-remitting multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing-remitting multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Relapsing-remitting multiple sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsing-remitting multiple sclerosis Emerging Drugs
Further product details are provided in the report..
Relapsing-remitting multiple sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Relapsing-remitting multiple sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
Relapsing-remitting multiple sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsing-remitting multiple sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing-remitting multiple sclerosis drugs.
Relapsing-remitting multiple sclerosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Relapsing-remitting multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Relapsing-remitting multiple sclerosis: Overview
Relapsing-remitting multiple sclerosis (RRMS) - the most common disease course – is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission.RRMS can be further characterized as either active (with relapses and/or evidence of new MRI activity over a specified period of time) or not active, as well as worsening (a confirmed increase in disability following a relapse) or not worsening. Approximately 85 percent of people with MS are initially diagnosed with RRMS.
'Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing-remitting multiple sclerosis pipeline landscape is provided which includes the disease overview and Relapsing-remitting multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing-remitting multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing-remitting multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing-remitting multiple sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Relapsing-remitting multiple sclerosis.
This segment of the Relapsing-remitting multiple sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsing-remitting multiple sclerosis Emerging Drugs
- Orelabrutinib: InnoCare Pharma
- BCD-063: Biocad
- Evobrutinib: Merck
Further product details are provided in the report..
Relapsing-remitting multiple sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Relapsing-remitting multiple sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Relapsing-remitting multiple sclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Relapsing-remitting multiple sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsing-remitting multiple sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing-remitting multiple sclerosis drugs.
Relapsing-remitting multiple sclerosis Report Insights
- Relapsing-remitting multiple sclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Relapsing-remitting multiple sclerosis drugs?
- How many Relapsing-remitting multiple sclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsing-remitting multiple sclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsing-remitting multiple sclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Relapsing-remitting multiple sclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- InnoCare Pharma
- Biocad
- Biogen
- RedHill Biopharma Limited
- Immunic AG
- Merck Serono
- Anokion SA
- Apitope Technology
- Neurotec Pharma
- Mitsubishi Tanabe Pharma Corporation
- TG Therapeutics, Inc.
- RemeGen Co., Ltd.
- Gilead Sciences
- GlaxoSmithKline
- GeNeuro SA
- InteKrin Therapeutics, Inc.
- Clene Nanomedicine
- Takeda Pharmaceuticals
- Mapi Pharma Ltd.
- Orelabrutinib
- BCD-063
- BIIB-019
- RHB-104
- IMU-838
- Evobrutinib
- ANK-700
- ATX-MS-1467
- NT-KO-003
- MT-1303
- TMP001
- Ublituximab
- RC18
- BCD-132
- TENOFOVIR ALAFENAMIDE
- Belimumab
- GNbAC1
- INT131
- CNM-Au8
- Ixazomib
- GA Depot
Introduction
Executive Summary
Relapsing-remitting multiple sclerosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Relapsing-remitting multiple sclerosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Relapsing-remitting multiple sclerosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsing-remitting multiple sclerosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Evobrutinib: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
RHB-104: RedHill Biopharma Limited
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Relapsing-remitting multiple sclerosis Key Companies
Relapsing-remitting multiple sclerosis Key Products
Relapsing-remitting multiple sclerosis- Unmet Needs
Relapsing-remitting multiple sclerosis- Market Drivers and Barriers
Relapsing-remitting multiple sclerosis- Future Perspectives and Conclusion
Relapsing-remitting multiple sclerosis Analyst Views
Relapsing-remitting multiple sclerosis Key Companies
Appendix
Executive Summary
Relapsing-remitting multiple sclerosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Relapsing-remitting multiple sclerosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Relapsing-remitting multiple sclerosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsing-remitting multiple sclerosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Evobrutinib: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
RHB-104: RedHill Biopharma Limited
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Relapsing-remitting multiple sclerosis Key Companies
Relapsing-remitting multiple sclerosis Key Products
Relapsing-remitting multiple sclerosis- Unmet Needs
Relapsing-remitting multiple sclerosis- Market Drivers and Barriers
Relapsing-remitting multiple sclerosis- Future Perspectives and Conclusion
Relapsing-remitting multiple sclerosis Analyst Views
Relapsing-remitting multiple sclerosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Relapsing-remitting multiple sclerosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Relapsing-remitting multiple sclerosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Relapsing-remitting multiple sclerosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Relapsing-remitting multiple sclerosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
